133 research outputs found
Does phase 2 of the expiratory PCO2 versus volume curve have diagnostic value in emphysema patients?
It has been postulated that serial inhomogeneity of ventilation in the
peripheral airways in emphysema is represented by the shape of expiratory
carbon dioxide tension versus volume curve. We examined the diagnostic
value of this test in patients with various degrees of emphysema. The
volumes between 25-50% (V25-50) and 25-75% (V25-75) of the expiratory
carbon dioxide tension versus volume curve were determined in 29
emphysematous patients (20 severely obstructed and 9 moderately
obstructed), 12 asthma patients in exacerbation of symptoms, and 28
healthy controls. Discriminant analysis was used to examine whether these
diagnostic groups could be separated. With regard to phase 2 of the
expiratory CO2 versus volume curve (mixture of anatomic deadspace and
alveolar air), a plot of intercept versus slope of the relationships of
(V25-50) and (V25-75) versus inspiratory volume (VI) from functional
residual capacity (FRC), obtained during natural breathing frequency,
proved to be most discriminating in the separation between healthy
controls and severely obstructed emphysema patients. Separating healthy
controls and severely obstructed emphysema patients on the basis of the
discriminant line for V25-50, 9 of the 12 asthma patients in exacerbation
were classified as normal, and only 5 of the 9 moderately obstructed
emphysema patients as emphysematous. For V25-75 involvement of phase 3 of
the curve (alveolar plateau) in asthma patients in exacerbation caused a
marked overlap with the severely obstructed emphysema patients. In the
healthy controls, a fixed breathing frequency of 20 breaths.min-1 led to
an increase of both volumes.(ABSTRACT TRUNCATED AT 250 WORDS
Dead space and slope indices from the expiratory carbon dioxide tension-volume curve
The slope of phase 3 and three noninvasively determined dead space
estimates derived from the expiratory carbon dioxide tension (PCO2) versus
volume curve, including the Bohr dead space (VD,Bohr), the Fowler dead
space (VD,Fowler) and pre-interface expirate (PIE), were investigated in
28 healthy control subjects, 12 asthma and 29 emphysema patients (20
severely obstructed and nine moderately obstructed) with the aim to
establish diagnostic value. Because breath volume and frequency are
closely related to CO2 elimination, the recording procedures included
varying breath volumes in all subjects during self-chosen/natural
breathing frequency, and fixed frequencies of 10, 15 and 20 breaths x
min(-1) with varying breath volumes only in the healthy controls. From the
relationships of the variables with tidal volume (VT), the values at 1 L
were estimated to compare the groups. The slopes of phase 3 and VD,Bohr at
1 L VT showed the most significant difference between controls and
patients with asthma or emphysema, compared to the other two dead space
estimates, and were related to the degree of airways obstruction.
Discrimination between no-emphysema (asthma and controls) and emphysema
patients was possible on the basis of a plot of intercept and slope of the
relationship between VD,Bohr and VT. A combination of both the slope of
phase 3 and VD,Bohr of a breath of 1 L was equally discriminating. The
influence of fixed frequencies in the controls did not change the results.
The conclusion is that Bohr dead space in relation to tidal volume seems
to have diagnostic properties separating patients with asthma from
patients with emphysema with the same degree of airways obstruction.
Equally discriminating was a combination of both phase 3 and Bohr dead
space of a breath of 1 L. The different pathophysiological mechanisms in
asthma and emphysema leading to airways obstruction are probably
responsible for these results
Trustworthy AI: Closing the gap between development and integration of AI systems in ophthalmic practice
Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Diabetic Macular Edema (BRDME):The BRDME Study, a Randomized Trial
Purpose: To generate conclusive evidence regarding the noninferiority of intravitreal bevacizumab compared with ranibizumab in patients with diabetic macular edema (DME). Design: Comparative, randomized, double-masked, multicenter, noninferiority clinical trial. Participants: Eligible patients were older than 18 years, diagnosed with type 1 or type 2 diabetes mellitus, with glycosylated hemoglobin of less than 12%, central area thickness of more than 325 μm, and visual impairment from DME with a best-corrected visual acuity (BCVA) between 24 letters and 78 letters. Methods: From June 2012 through February 2018, a total of 170 participants were randomized to receive 6 monthly injections of either 1.25 mg bevacizumab (n = 86) or 0.5 mg ranibizumab (n = 84). Main Outcome Measures: Primary outcome was change in BCVA from baseline to month 6 compared between the 2 treatment arms. The noninferiority margin was 3.5 letters. Results: The difference in mean BCVA between treatment arms was 1.8 letters in favor of ranibizumab after 6 months of follow-up; BCVA improved by 4.9±6.7 letters in the bevacizumab group and 6.7±8.7 letters in the ranibizumab group. The lower bound of the 2-sided 90% confidence interval (CI) was –3.626 letters, exceeding the noninferiority margin of 3.5 letters. Central area thickness decreased more with ranibizumab (138.2±114.3 μm) compared with bevacizumab (64.2±104.2 μm). In a post hoc subgroup analysis, participants with a worse BCVA at baseline (≤69 letters) improved by 6.7±7.0 letters with bevacizumab and 10.4±10.0 letters with ranibizumab, and central area thickness decreased significantly more in the ranibizumab arm of this subgroup compared with the bevacizumab arm. Participants with an initially better BCVA at baseline (≥70 letters) did not demonstrate differences in BCVA or OCT outcomes between treatment arms. Conclusions: Based on change in BCVA from baseline to month 6, the noninferiority of 1.25 mg bevacizumab to 0.5 mg ranibizumab was not confirmed. Only the subgroup of patients with a lower BCVA at baseline showed better visual acuity and anatomic outcomes with ranibizumab. Our study confirmed the potential differential efficacy of anti–vascular endothelial growth factor agents in the treatment of DME as well as the difference in response between patient groups with different baseline visual acuities
Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Retinal Vein Occlusion:The Bevacizumab to Ranibizumab in Retinal Vein Occlusions (BRVO) study, a Randomized Trial
PURPOSE: Comparing the efficacy of intravitreal injections of bevacizumab to ranibizumab in the treatment of macular edema (ME) resulting from retinal vein occlusion (RVO). DESIGN: Comparative, randomized, double-masked, multicenter, noninferiority clinical trial. The noninferiority margin was 4 letters. PARTICIPANTS: Patients with vision loss resulting from ME secondary to a branch or (hemi) central RVO who might benefit from anti-vascular endothelial growth factor treatment were eligible for participation. METHODS: From June 2012 through February 2018, 277 participants were randomized to receive injections of 1.25 mg bevacizumab (n = 139) or 0.5 mg ranibizumab (n = 138). The follow-up was 6 months with a monthly dosing interval. MAIN OUTCOME MEASURES: The primary outcome was a change in visual acuity from baseline at 6 months. Changes in the central area thickness and safety were studied as secondary outcomes. RESULTS: The mean visual acuity (±standard deviation) improved, with 15.3±13.0 letters for bevacizumab and 15.5±13.3 letters for ranibizumab after 6 months of monthly treatment. The lower limit of the 2-sided 90% confidence interval was -1.724 letters, which is within the noninferiority margin of 4 letters. Even in the branch and (hemi-)central RVO subgroups, minimal differences were found in visual acuity outcomes between treatment arms. Changes in central area thickness on OCT at 6 months did not differ significantly between treatment groups, with a decrease of 287.0±231.3 μm in the bevacizumab group and 300.8±224.8 μm in the ranibizumab group. Severe adverse events (SAEs) were also distributed equally over both treatment groups: 10 participants (7.1%) in the bevacizumab group and 13 participants (9.2%) in the ranibizumab group experienced SAEs. CONCLUSIONS: This study showed, based on the change in visual acuity, that bevacizumab is noninferior to ranibizumab for patients with ME resulting from RVO of either subtype when receiving monthly injections for a period of 6 months. In addition, anatomic and safety outcomes did not differ between treatment groups. Based on our findings, bevacizumab may be an effective alternative to ranibizumab
Optimising Psychoeducation for Transient Ischaemic Attack and Minor Stroke Management (OPTIMISM): Protocol for a feasibility randomised controlled trial
Background: A transient ischaemic attack (TIA) and minor stroke are medical emergencies and often a warning sign of future strokes if remain untreated. Few studies have investigated the long-term psychosocial effects of TIA and minor stroke. Secondary prevention and medical management are often the primary focus with limited access offered for further psychosocial support. Psychoeducational interventions can provide education and advice to people with physical health conditions and, with suitable tailoring, could be appropriate for people after TIA and minor stroke. This study aims to develop a group psychoeducational intervention for people after TIA and minor stroke and to test whether it is acceptable and feasible.
Methods: This mixed-methodology study involves two phases: Phase 1) A qualitative study to determine the content of a suitable intervention; Phase 2) A single-centre feasibility randomised controlled trial to evaluate the acceptability of this intervention. The overall study has ethical approval. Stroke survivors have been involved in designing and monitoring the trial. The aim is to recruit 30-40 participants from a Stroke/TIA Service, within 6 months following their diagnosis. Participants will be randomly allocated to either the usual care control group or the intervention group (psychoeducational programme). The programme will consist of six group sessions based on providing education, psychological and social support. The primary outcomes will relate to the feasibility aims of the study. Outcomes will be collected at 3 and 6 months to assess mood, quality of life, knowledge and satisfaction, and resource use.
Discussion: There is a need to develop and evaluate effective interventions that enhance the education provided to people after TIA and minor stroke and to promote their psychosocial wellbeing. Findings will indicate the acceptability of the intervention and parameters needed to conduct a definitive trial
Cognitive function and drivers of cognitive impairment in a European and a Korean cohort of people living with HIV
Although cognitive impairments are still prevalent in the current antiretroviral therapy era, limited investigations have compared the prevalence of cognitive disorder in people living with HIV (PLWH) and its determinants in different regions and ethnicities. We compared cognitive performance across six domains using comparable batteries in 134 PLWH aged ≥45 years from the COBRA study (Netherlands, UK), and 194 PLWH aged ≥18 years from the NeuroAIDS Project (South Korea). Cognitive scores were standardized and averaged to obtain domain and global T-scores. Associations with global T-scores were evaluated using multivariable regression and the ability of individual tests to detect cognitive impairment (global T-score ≤45) was assessed using the area-under-the-receiver-operating-characteristic curve (AUROC). The median (interquartile range) age of participants was 56 (51, 62) years in COBRA (88% white ethnicity, 93% male) and 45 (37, 52) years in NeuroAIDS (100% Korean ethnicity, 94% male). The rate of cognitive impairment was 18.8% and 18.0%, respectively (p = 0.86). In COBRA, Black-African ethnicity was the factor most strongly associated with cognitive function (11.1 [7.7, 14.5] lower scores vs. white ethnicity, p < 0.01), whereas in NeuroAIDS, age (0.6 [0.1, 1.3] per 10-year, p<0.01) and education (0.7 [0.5, 0.9] per year, p<0.01) were significantly associated with cognitive function with anemia showing only a weak association (−1.2 [−2.6, 0.3], p=0.12). Cognitive domains most associated with cognitive impairment were attention (AUROC = 0.86) and executive function (AUROC = 0.87) in COBRA and processing speed (AUROC = 0.80), motor function (AUROC = 0.78) and language (AUROC = 0.78) in NeuroAIDS. Two cohorts of PLWH from different geographical regions report similar rates of cognitive impairment but different risk factors and cognitive profiles of impairment
- …